Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on March 21, 2022. The Company is an emerging growth company incorporated in Nevada with its principal executive offices in Boca Raton, Florida. The report details the approval of stock option grants under the Company's 2021 Stock Incentive Plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on equity compensation arrangements.
Material Changes and Option Grants
On March 21, 2022, the Compensation Committee approved the following option grants from the 2021 Plan, all with an exercise price of $7.92 per share:
- Non-Employee Directors: An aggregate of 175,000 shares (35,000 shares per director).
- Chief Executive Officer (Ramond J. Tesi): 130,000 shares.
- Chief Financial Officer (David Moss): 130,000 shares.
- Chief Scientific Officer (Mark Lowdell): 104,000 shares.
Vesting Schedule: For all grants, one-third (1/3) of the options vest on the one-year anniversary of the grant date. The remaining options vest monthly at a rate of 1/24th thereafter, achieving 100% vesting on the three-year anniversary of the grant date.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, financial guidance, risks, contingencies, or unusual items. The document serves solely to disclose the specific equity compensation actions taken by the Board.
Investor Verification Checklist
- Verify the total number of shares remaining available for issuance under the 2021 Stock Incentive Plan after these grants.
- Confirm the fair value of the options granted for potential stock-based compensation expense recognition in future financial statements.
- Review the attached Form of Option Agreement (Exhibits 10.1 and 10.2) for specific terms and conditions not detailed in the summary.
- Monitor future filings for the execution of the stock option agreements with the named executives and directors.